Eli Lilly (LLY) Could Be 24% Below Fair Value As Revenue Outlook Rises

Eli Lilly (LLY) is back in focus after reporting second quarter 2026 results and lifting its full year revenue outlook to US$85b to US$87b, giving investors fresh numbers to assess.

See our latest analysis for Eli Lilly.

Eli Lilly’s share price has pulled back recently, with a 7 day share price return of 8.6% lower and a 30 day share price return of 8.1% lower, even though the 1 year total shareholder return is 46.69% and the 5 year total shareholder return is very large at 334.06%.

If Eli Lilly’s GLP-1 story has your attention, it may be a good moment to broaden your watchlist with other healthcare stocks using the 41 healthcare AI stocks.

Eli Lilly now trades below both the in house fair value estimate and the average analyst price target after a sharp pullback. Is this a healthy reset after a big run, or a sign the market doubts the story?

Most Popular Narrative: 24.5% Undervalued

Eli Lilly’s last close of $1,115.68 sits well below the fair value of $1,477.03 in the most followed narrative, which frames the current pullback as a valuation gap rather than a full reset.

Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet.

The pricing headwinds are real, but they are happening to a company with manufacturing scale, regulatory depth, and a next-generation compound that has already beaten the highest analyst expectations in Phase 3.

Read the complete narrative. Read the complete narrative.

Curious what sits behind that $1,477.03 fair value for Eli Lilly? The narrative leans heavily on expectations for sustained earnings expansion, robust margins and a future profit multiple usually reserved for faster growing sectors. The mix of pipeline expectations, growth assumptions and discounting choices may surprise you.

Result: Fair Value of $1,477.03 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Eli Lilly narrative still hinges on GLP-1 pricing pressure and future trial outcomes, which could quickly challenge the current undervaluation story.

Find out about the key risks to this Eli Lilly narrative.

Next Steps

With Eli Lilly, the story clearly has both strong supporters and cautious skeptics, so move quickly to review the full picture and decide where you stand, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Eli Lilly?

If Eli Lilly has sharpened your focus on quality, now is the moment to widen your search and uncover other stocks that could strengthen your portfolio.

• Spot potential value opportunities early by reviewing companies that appear mispriced on fundamentals using the 52 high quality undervalued stocks.
• Build a steadier core in your portfolio by focusing on companies with reliable balance sheets through the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for under-the-radar potential by checking the screener containing 18 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com